Sun Pharma has announced a landmark definitive agreement to acquire Organon in an all-cash transaction valued at approximately $11.75 billion, marking one of the most significant strategic moves in the global pharmaceutical industry this year. Under the agreement, Organon shareholders will receive $14 per share, with the transaction expected to close in early 2027, subject to regulatory and shareholder approvals.
The acquisition is set to significantly strengthen Sun Pharma’s global presence while accelerating its expansion into women’s health, biosimilars, and established branded medicines. Organon, a global healthcare company spun off from Merck in 2021, brings a portfolio of more than 70 products across women’s health, general medicines, and biosimilars, with operations spanning over 140 markets.By combining Organon’s women’s health leadership and biosimilar capabilities with Sun Pharma’s growing innovation-focused business, the deal is expected to position Sun Pharma among the world’s top 25 pharmaceutical companies, with a broader footprint across 150 countries.
Sun Pharma leadership described the acquisition as a transformational step toward building a more diversified, innovation-driven healthcare enterprise. Beyond financial scale, the move reflects a strategic commitment to expanding access to critical therapies worldwide, particularly in women’s healthcare, while strengthening long-term global competitiveness.
By Arundhuti Chatterjee & Sharon Bose
